Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 5/20 | 0.76 |
| ▸ | RPS6KB1 | P23443 | 5/20 | 0.71 |
| ▸ | GSK3B | P49841 | 5/20 | 0.71 |
| ▸ | PRKACA | P17612 | 4/20 | 0.71 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.71 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.71 |
| ▸ | TP53 | P04637 | 3/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | ATM | Q13315 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 5/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | KCNK13 | Q9HB14 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1901013 | 0.86 | HTT (1.00) | HTTRPS6KB1GSK3BPRKACAROCK1 | |
| SCHEMBL6401508 | 0.85 | HTT (0.79) | HTTRPS6KB1GSK3BPRKACAROCK1 | |
| SCHEMBL6406327 | 0.84 | HTT (1.00) | HTTRPS6KB1GSK3BPRKACAROCK1 | |
| SCHEMBL1899581 | 0.84 | HTT (0.77) | HTTRPS6KB1GSK3BPRKACAROCK1 | |
| Gw549034X SCHEMBL1900661 | 0.83 | RPS6KA5 (1.00) | HTTRPS6KB1GSK3BPRKACAROCK1 | |
| SCHEMBL1907407 | 0.83 | HTT (0.93) | HTTRPS6KB1GSK3BPRKACAROCK1 | |
| SCHEMBL1905525 | 0.83 | HTT (1.00) | HTTRPS6KB1GSK3BPRKACAROCK1 | |
| SCHEMBL14364660 | 0.83 | HTT (0.76) | HTTRPS6KB1GSK3BPRKACAROCK1 | |
| SCHEMBL14364655 | 0.81 | HTT (0.78) | HTTRPS6KB1GSK3BPRKACAROCK1 | |
| SCHEMBL14364657 | 0.81 | KDM4E (0.77) | HTTRPS6KB1GSK3BPRKACAROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2322521-B1 | Heteroaryl compounds useful as inhibitors of GSK-3 | VERTEX PHARMA (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20070270420-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
| US-20070270420-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
| US-20050153978-A1 | Medicaments | GLAXO GROUP LIMITED (GB) | 2005-07-14 | — | — | US | disclosed |
| EP-1487441-A2 | BENZIMIDAZOLES AND THEIR USE AS MITOGEN-ACTIVATED- AND RHO-KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003080125-A2 | BENZIMIDAZOLES AND THEIR USE AS MITOGEN-ACTIVATED- AND RHO-KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270420-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | GSK3B, GSK3A, GSKIP | HTT 3199/4885RPS6KB1 417/4885GSK3B 1/4885 |
| US-20050153978-A1 | Medicaments | GRK1, ROCK1, GRK7 | HTT 4712/4885RPS6KB1 63/4885GSK3B 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.